**Health**
## Experts Urge NHS to Overhaul Obesity Treatment Strategy Amid Soaring Demand for Weight Loss Medications
**LONDON** – Leading health experts are calling for an urgent and comprehensive review of NHS obesity treatment services, warning that the healthcare system is ill-equipped to handle the escalating demand for new weight loss medications like GLP-1 agonists.
The call comes amidst a surge in public and clinical interest in glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (marketed as Wegovy for weight loss, and Ozempic primarily for diabetes), which have demonstrated significant efficacy in promoting weight loss and improving metabolic health. This success, however, has placed unprecedented pressure on already stretched NHS weight management clinics and primary care services.
Experts emphasize that the current approach, largely fragmented and under-resourced, is unsustainable. They argue that a robust national strategy is urgently needed to integrate these new pharmacological treatments with existing lifestyle interventions, nutritional support, and psychological counselling. The aim is not merely to provide prescriptions but to ensure comprehensive, long-term management for individuals living with obesity.
Obesity is a complex, chronic disease, and while these new medications offer a powerful tool, their introduction requires significant systemic adjustments. Concerns have been raised regarding equitable access, funding mechanisms, and the adequate training of healthcare professionals to manage patients on these therapies effectively and safely. Without a cohesive plan, there’s a risk of widening health inequalities and creating a ‘postcode lottery’ for treatment.
The proposed review should critically assess the entire pathway for obesity care within the NHS, from initial assessment and diagnosis in primary care to specialist referral and ongoing support. This includes evaluating the capacity of existing clinics, the availability of multi-disciplinary teams, and the long-term cost-effectiveness and sustainability of widespread GLP-1 agonist prescription. The ultimate goal, experts contend, is to establish a future-proof framework that delivers consistent, high-quality care to all eligible patients across the UK.
The coming months will be crucial in determining whether the NHS can adapt its strategy to meet the evolving landscape of obesity treatment and provide effective solutions for millions affected by the condition.
